**Research-Only Disclaimer:** All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.

If you’re looking for the most complete LGD-4033 research guide available, you’re in the right place. Ligandrol (LGD-4033) has become one of the most studied selective androgen receptor modulators in performance research — and for good reason. The data coming out of results-driven studies consistently shows why this compound dominates conversations around lean mass research and anabolic performance.

Whether you’re a seasoned researcher or just starting to explore SARMs, this guide breaks down everything the current literature reveals about LGD-4033: how it works, what studies show, how it stacks up against other research compounds, and what makes it stand out in the SARMs research guide landscape.

What Is LGD-4033 (Ligandrol)?

LGD-4033 — commonly known as Ligandrol — is a non-steroidal selective androgen receptor modulator (SARM) developed to target androgen receptors in muscle and bone tissue with high specificity. Unlike traditional anabolic agents that flood the entire body with androgenic activity, LGD-4033 was designed to bind selectively, delivering potent anabolic signaling where researchers want it while minimizing off-target effects.

Originally developed by Ligand Pharmaceuticals, LGD-4033 has been the subject of multiple clinical and preclinical investigations. Its anabolic potency is among the highest in the SARM class, which is exactly why it remains a top-tier compound for performance research.

In the context of lgd-4033 canada demand, this compound has surged in popularity among researchers focused on muscle tissue models, anabolic signaling pathways, and body recomposition studies. BioPharma supplies LGD-4033 exclusively for in vitro research applications.

How LGD-4033 Works: Mechanism of Action

LGD-4033 works by binding directly to androgen receptors (AR) in skeletal muscle and bone tissue. Once bound, it triggers conformational changes in the AR that promote anabolic gene expression — essentially flipping the switch for muscle protein synthesis without the broad systemic androgenic activation seen with traditional compounds.

Key mechanism highlights:

  • Selective AR binding: LGD-4033 demonstrates a binding affinity that rivals testosterone but with tissue selectivity that focuses activity on muscle and bone
  • Anabolic gene upregulation: Activates transcription of genes responsible for muscle growth and bone density in research models
  • Reduced 5α-reductase conversion: Unlike testosterone, LGD-4033 does not convert to DHT in peripheral tissues, reducing androgenic side effects in study models
  • No aromatization: The compound does not aromatize to estrogen, which differentiates it from many traditional anabolic compounds used in research

This selectivity profile is what makes LGD-4033 research so compelling for researchers who want anabolic data points without the collateral androgenic activity that complicates study outcomes.

What the Research Shows: LGD-4033 Study Results

The lgd 4033 SARM research base includes both preclinical and human clinical trials — something relatively rare in the SARM space. Here’s what the data tells us:

Phase 1 Clinical Trial (Basaria et al., 2013)

The most frequently cited LGD-4033 study was a randomized, double-blind, placebo-controlled Phase 1 trial in healthy volunteers. Key findings:

  • Lean body mass increased in a dose-dependent manner across all treatment groups
  • Statistically significant gains observed at doses as low as 0.1 mg/day in the 21-day study window
  • No serious adverse events reported during the trial duration
  • Serum testosterone suppression was observed at higher doses, a critical data point for researchers planning long-term protocols

Preclinical Muscle Research

Animal models have demonstrated:

  • Substantial increases in lean mass compared to control groups
  • Significant anabolic effects on both muscle and bone tissue
  • Dose-dependent responses that plateau at higher concentrations, suggesting a ceiling effect researchers should account for

Ligandrol Research: Emerging Data

Ongoing ligandrol research continues to explore:

  • Optimal dosing windows for maximizing anabolic output in tissue models
  • Potential applications in muscle wasting conditions (though BioPharma compounds are sold for in vitro use only)
  • Stacking protocols with other SARMs and research compounds for combined pathway activation

LGD-4033 vs. Other Research Compounds

How does LGD-4033 compare to other popular SARMs in performance research? Here’s a direct breakdown:

| Feature | LGD-4033 | RAD-140 | MK-2866 |

|—|—|—|—|

| Primary Focus | Lean mass, anabolic signaling | Strength, aggression pathways | Tissue preservation, recomp |

| Anabolic Potency | Very High | Very High | Moderate |

| Selectivity | High (muscle/bone) | High (muscle/brain) | High (muscle/joint) |

| Research Popularity | #1 for size studies | #1 for strength studies | #1 for recomp studies |

| Suppression Profile | Moderate-High | Moderate-High | Low-Moderate |

| Half-life (research) | 24-36 hours | 16-18 hours | 24 hours |

LGD-4033 sits at the top for researchers focused purely on anabolic output and lean mass data. If your research priorities are different, the RAD-140 research guide covers the strength-focused alternative, and the MK-2866 research guide breaks down the milder, tissue-preservation side of the SARM spectrum.

Research Protocols: What the Literature Suggests

When reviewing published protocols and research methodology, LGD-4033 studies typically follow these frameworks:

Common research concentration ranges used in published studies:

  • 0.1 mg/day — Low-end dose used in Phase 1 trials; measurable but modest anabolic response
  • 1.0 mg/day — Mid-range dose showing significant lean mass increases in clinical data
  • 2.0 mg/day and above — Higher concentrations studied for maximum anabolic output; associated with greater suppression in androgen markers

Study duration patterns:

  • Acute studies: 14–21 days (baseline pharmacokinetic and safety data)
  • Extended protocols: 8–12 weeks (common in performance research setups)
  • Recovery phase monitoring: 4–8 weeks post-compound observation for HPTA recovery data

Important: These protocol details reference published research for informational purposes only. BioPharma sells LGD-4033 strictly for in vitro research use.

LGD-4033 Canada: Sourcing Research-Grade Compounds

For researchers in Canada sourcing lgd-4033 canada supply, quality and consistency are non-negotiable. The research compound market is flooded with underdosed, mislabeled, and contaminated products that can destroy study validity before you even begin.

What to demand from your research compound supplier:

  • Third-party testing with publicly available Certificates of Analysis (CoA)
  • Purity standards at 98%+ for reliable, reproducible data
  • Consistent batch-to-batch quality so your results aren’t confounded by variable compound integrity
  • Transparent sourcing and formulation — know exactly what’s in the bottle

BioPharma supplies LGD-4033 with full CoA documentation, third-party verified purity, and the consistency your research demands. Shop LGD-4033 →

Frequently Asked Questions

What is LGD-4033 used for in research?

LGD-4033 is studied primarily for its anabolic effects on skeletal muscle and bone tissue. Researchers use it to investigate selective androgen receptor activation, lean mass accumulation pathways, and potential applications in muscle-wasting conditions. BioPharma sells LGD-4033 for in vitro research purposes only.

How does LGD-4033 compare to RAD-140?

Both are high-potency SARMs, but they serve different research goals. LGD-4033 is typically preferred for lean mass accumulation studies, while RAD-140 is favored for strength and neuromuscular research. Both show moderate-to-high androgen suppression at effective research doses. See the RAD-140 research guide for a deeper comparison.

Does LGD-4033 show up in research models as suppressive?

Yes. Clinical data confirms that LGD-4033 causes dose-dependent suppression of endogenous testosterone at research-relevant concentrations. This is an important variable for researchers to monitor, and recovery-phase protocols are standard in published studies.

What purity level should LGD-4033 research compounds meet?

For reproducible, publication-quality data, LGD-4033 should meet or exceed 98% purity with third-party verification. Lower purity compounds introduce confounding variables that can compromise study results.

Can LGD-4033 be stacked with other research compounds?

Some published protocols and community research logs combine LGD-4033 with other SARMs or compounds for multi-pathway studies. However, stacking increases the complexity of data interpretation and suppression monitoring. Each compound should be well-characterized individually before combining. Explore the full SARMs research guide for broader context.

Is LGD-4033 legal to purchase in Canada for research?

LGD-4033 can be legally sold and purchased for in vitro research purposes in Canada. It is not approved for human consumption. Researchers should verify their institutional and local regulations before purchasing.

Related Research Guides

Get LGD-4033 for Your Research

When your studies demand the most anabolic SARM in the research arsenal, LGD-4033 delivers the data. BioPharma supplies research-grade Ligandrol with verified purity, full CoA documentation, and the consistency your protocols require.

Shop LGD-4033 →

All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice. Results referenced are from published research and may not reflect outcomes from your specific protocols.